Literature DB >> 29062616

Association of Internal Mammary Artery Flow with Different Comorbidities and Post-Coronary Artery Bypass Graft Complications.

Mudassir Iqbal Dar1, Asim Hassan Dar2, Muhammad Bilal3, Mansoor Ahmad4, Abdul Haseeb3.   

Abstract

Objective The internal mammary artery (IMA) is commonly used arterial graft for coronary artery bypass surgery (CABG). The IMA has a better patency and survival. This study considers different comorbidities and conditions where IMA flow may be low. Therefore, the main objective is to determine the flow of IMA in different diseases, its relation to gender, age, and in different blood groups in order to prevent possible complications. Methods A prospective study was conducted at the Cardiac Surgery Unit, Civil Hospital Karachi from January 2013 to December 2015. The data of 158 patients who underwent primary, isolated, and CABG surgery was collected. Free flow of IMA was measured immediately after harvesting for 30 seconds within a syringe, and its relationship with different diseases and conditions was examined. Data was collected using a structured questionnaire from the patients' medical record files and it was later analyzed and entered into the Statistical Package for Social Sciences (SPSS) software, V17 (IBM SPSS Statistics, Armonk, NY). Results The mean flow was 11.6 ± 9.6 ml. There was no difference in flow related to gender, diabetes, smoking, renal disease, and chronic obstructive pulmonary disease (COPD). There was significantly higher flow in the age group of 50 to 60 years (p = 0.002), hypertensive patients (p = 0.016), patients with liver disease (p = 0.001), BMI > 30 (p = 0.041), and the blood group AB+ (p = 0.02). The atrial fibrillation and readmissions were higher in patients who had low flow. Low flow IMA, which was used on left anterior descending (LAD) artery stenosis patients, showed a significantly higher need of pharmacological and mechanical support. Conclusion IMA should be used carefully in patients where its flow is low; conditions must be analyzed where flow may be low to avoid complications. Further studies are warranted.

Entities:  

Keywords:  cabg; ima flow; internal mammary artery; postoperative complications

Year:  2017        PMID: 29062616      PMCID: PMC5650253          DOI: 10.7759/cureus.1584

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  16 in total

1.  Left internal mammary artery to the left anterior descending artery: effect on morbidity and mortality and reasons for nonusage.

Authors:  Shishir Karthik; Arun K Srinivasan; Antony D Grayson; Mark Jackson; Neeraj K Mediratta
Journal:  Ann Thorac Surg       Date:  2004-07       Impact factor: 4.330

2.  Why is the mammary artery so special and what protects it from atherosclerosis?

Authors:  Fumiyuki Otsuka; Kazuyuki Yahagi; Kenichi Sakakura; Renu Virmani
Journal:  Ann Cardiothorac Surg       Date:  2013-07

3.  Coronary artery bypass. The physiological basis for differences in flow with internal mammary artery and saphenous vein grafts.

Authors:  P Dobrin; T Canfield; J Moran; H Sullivan; R Pifarré
Journal:  J Thorac Cardiovasc Surg       Date:  1977-09       Impact factor: 5.209

4.  Early postoperative spasm in left internal mammary artery bypass grafts.

Authors:  M R Sarabu; J A McClung; A Fass; G E Reed
Journal:  Ann Thorac Surg       Date:  1987-08       Impact factor: 4.330

5.  Flow in coronary bypass conduits on-pump and off-pump.

Authors:  Henrik K Kjaergard; Akhmad Irmukhamedov; John B Christensen; Thomas A Schmidt
Journal:  Ann Thorac Surg       Date:  2004-12       Impact factor: 4.330

6.  The effect of nebivolol on internal mammary artery blood flow during coronary artery bypass graft surgery.

Authors:  S Sarikaya; A Onk; B Boztosun; G Kocabay; M Sahin; A Fedakar; C Köksal
Journal:  Perfusion       Date:  2013-12-20       Impact factor: 1.972

7.  Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial.

Authors:  Ralf E Harskamp; John H Alexander; T Bruce Ferguson; Rebecca Hager; Michael J Mack; Brian Englum; Daniel Wojdyla; Phillip J Schulte; Nicholas T Kouchoukos; Robbert J de Winter; C Michael Gibson; Eric D Peterson; Robert A Harrington; Peter K Smith; Renato D Lopes
Journal:  Circulation       Date:  2015-12-08       Impact factor: 29.690

8.  Inadequate internal mammary artery graft as a cause of postoperative ischemia: incidence, diagnosis and management.

Authors:  P Vajtai; P S Ravichandran; C L Fessler; H S Floten; A Ahmad; H L Gately; J S Swanson; A Starr
Journal:  Eur J Cardiothorac Surg       Date:  1992       Impact factor: 4.191

9.  Role of gender, smoking profile, hypertension, and diabetes on saphenous vein and internal mammary artery endothelial relaxation in patients with coronary artery bypass grafting.

Authors:  Andrew Duncan Muir; Pascal Patrick McKeown; Ulvi Bayraktutan
Journal:  Oxid Med Cell Longev       Date:  2010 May-Jun       Impact factor: 6.543

10.  Cigarette smoking leads to reduced relaxant responses of the cutaneous microcirculation.

Authors:  Marie-Louise Edvinsson; Sven E Andersson; Cang-Bao Xu; Lars Edvinsson
Journal:  Vasc Health Risk Manag       Date:  2008
View more
  2 in total

1.  Outcomes and Patency of Complex Configurations of Composite Grafts Using Bilateral Internal Thoracic Arteries.

Authors:  Beatrice Chia-Hui Shih; Suryeun Chung; Hakju Kim; Hyoung Woo Chang; Dong Jung Kim; Cheong Lim; Kay-Hyun Park; Jun Sung Kim
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2020-04-05

2.  Differences in Expression of Genes Involved in Bone Development and Morphogenesis in the Walls of Internal Thoracic Artery and Saphenous Vein Conduits May Provide Markers Useful for Evaluation Graft Patency.

Authors:  Mariusz J Nawrocki; Bartłomiej Perek; Patrycja Sujka-Kordowska; Aneta Konwerska; Sandra Kałużna; Piotr Zawierucha; Małgorzata Bruska; Maciej Zabel; Marek Jemielity; Michał Nowicki; Bartosz Kempisty; Agnieszka Malińska
Journal:  Int J Mol Sci       Date:  2019-10-02       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.